Distinct Type of Myeloid Neoplasms Characterized by Germline DDX41 Mutations
Researchers conducted a retrospective study to comprehensively characterize DDX41 mutations in a multinational cohort of patients with MNs.
Diagnosis & Disease Information
Momelotinib Found Superior to Danazol for the Treatment of Myelofibrosis
Researchers sought to determine if momelotinib provided better improvements in anemia in patients with myelofibrosis, compared with treatment with danazol.
Associations of Mutations in Spliceosome Genes With Ring Sideroblasts Verified in Myelodysplastic Syndromes
Researchers sought to verify the association of mutations in the splicing pathway gene SF3B1 with low bone marrow blast counts and increased ring sideroblasts in MDS.
Monoclonal Antibody Shows Promise for Treating MPNs in Preclinical Study
Preclinical research suggests that a monoclonal antibody may be effective for treating CALR-mutant myeloproliferative neoplasms.
Best Practices for Effective MPN Case Management in the Outpatient Setting
The symptoms and care needs of patients with myeloproliferative neoplasms are discussed in a report on effective care management for these patients.
Lenalidomide May Select for TP53-Mutated Clones, Increasing Risk of Therapy-Related MNs
Researchers sought to determine the role of lenalidomide in the pathogenesis of therapy-related myeloid neoplasms.
Endoscopic Procedures Improve Gastroesophageal Variceal Rebleeding in MPN
Researchers sought to determine the efficacy of endoscopic management of recurrent GVB in patients with MPN.
Risk Factors Identified for Secondary Myeloid Neoplasms in Aplastic Anemia, PNH
Researchers sought to determine risk factors for developing secondary myeloid neoplasm in patients with severe aplastic anemia.
Risk of Arterial Thrombosis Higher With COVID-19 in Patients With Myeloproliferative Neoplasms
Researchers sought to determine whether there was a higher risk of developing thrombosis in patients with MPNs and COVID-19.
Pemazyre Approved for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
The approval was based on data from the phase 2 FIGHT-203 study, which included 28 patients with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
- Loading...
Loading...
Next post in General Hematology
Loading... 
Loading...